PROCEPT BioRobotics Reports Q4 2025 Results, Cuts 2026 Revenue Guidance Amid Strategic Realignment
Summary
PROCEPT BioRobotics reported Q4 2025 results with 12% revenue growth but widened losses, and significantly cut its full-year 2026 revenue guidance due to strategic realignments and a revised handpiece sales strategy.
Key Events
-
Q4 2025 Financial Performance
Reported total revenue of $76.4 million, a 12% increase year-over-year, driven by a 69% increase in U.S. procedures to approximately 12,200. However, the company's net loss widened to $29.8 million from $18.9 million in the prior year period.
-
2026 Revenue Guidance Cut
The company reset its full-year 2026 revenue guidance to a range of $390 million to $410 million, representing 27% to 33% growth. This is a reduction from previous expectations, attributed to aligning handpiece unit sales with procedure volumes and short-term disruption from sales force realignment.
-
Strategic Commercial Realignment
Management implemented a realignment of its commercial organization, established a dedicated launch team, and adopted a more disciplined handpiece pricing strategy, which led to a Q4 revenue shortfall but improved handpiece average selling price by 5% sequentially.
-
Cash Position
As of December 31, 2025, cash, cash equivalents, and restricted cash totaled $289.5 million.
Analysis
PROCEPT BioRobotics reported mixed Q4 2025 financial results, with revenue growth but increased net losses. The most significant development is the company's decision to reset its full-year 2026 revenue guidance to a range of $390 million to $410 million, representing 27% to 33% annual growth. This guidance cut, explicitly attributed to a realignment of the commercial organization and a revised handpiece pricing strategy, implies a reduction from prior expectations. The company noted a Q4 revenue shortfall and reduced projected 2026 handpiece revenue guidance, although partially offset by higher handpiece average selling prices. This news comes as the stock is trading at new lows, making the downward revision in guidance particularly impactful for investor sentiment and the company's near-term outlook.
At the time of this filing, PRCT was trading at $19.31 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $26.23 to $70.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.